Finding Growth In China
34:33–35:26 · 53s
Batra contrasts pressured Chinese generics with booming innovation—one-third of in-licensed molecules now originate in China—driving 50% pharma growth for Waters there.
34:33–35:26 · 53s
Batra contrasts pressured Chinese generics with booming innovation—one-third of in-licensed molecules now originate in China—driving 50% pharma growth for Waters there.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.